MedTrace Logo

Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain

NCT06411067 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2025-08-14

No results posted yet for this study

Summary

The purpose of this study is to determine if the administration of the CGRP-receptor antagonist erenumab is effective in decreasing pain and improving quality of life in patients with FMS by comparing the difference in pain scores in Fibromyalgia Impact Questionnaire, defense and veterans Pain Rating Scale and The American College of Rheumatology 2010 Preliminary Diagnostic Criteria for Fibromyalgia score over the study period.

Conditions

  • Fibromyalgia

Interventions

DRUG

Erenumab

Monthly injection of erenumab for fibromyalgia

DRUG

Saline

Monthly injection of 0.9% saline for control

Sponsors & Collaborators

  • United States Naval Medical Center, Portsmouth

    lead FED

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-26
Primary Completion
2022-05-09
Completion
2022-05-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06411067 on ClinicalTrials.gov